The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

European Commission approves Onureg for certain AML subtypes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The European Commission has approved Onureg (azacitidine tablets)as the first and only once-daily, frontline oral maintenance therapy in the EU for patients with a broad range of acute myeloid leukemia subtypes. 

While many patients with AML achieve remission with induction therapy, about 50% of patients relapse within one year. In the pivotal QUAZAR AML-001 study, Onureg significantly improved overall survival and relapse-free survival in patients with AML, reinforcing its clinical benefit and role in the treatment paradigm for patients with this common acute leukemia.

Onureg is sponsored by Bristol Myers Squibb.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account